Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,191 total articles
Serina Therapeutics completed enrollment and dosing for Cohort 1 of its Phase 1b registrational study of SER-252 ahead of schedule. The single-ascending-dose data top line results are expected in the first half of 2027. The company also announced a development partnership with Gannet BioChem for manufacturing support and appointed Farrell Simon, Ph…
Lianhe Sowell International Group Ltd announced its fiscal year 2026 financial results, reporting an 18% increase in total revenues to $43.27 million driven by 40% growth in electronic products. Despite top-line growth, the company posted a net loss of $5.65 million due to a 148% surge in operating expenses fueled by strategic investments in R&D an…
Martin Marietta Materials, Inc. has increased its quarterly cash dividend from $0.83 to $0.84 per share, marking its eleventh consecutive annual dividend raise. The dividend is payable on September 30, 2026, to shareholders of record as of September 1, 2026. The company highlights its strong cash flow, durable business model, and confidence in sust…
AmpliTech Group, a US-based manufacturer of advanced RF and microwave components, announced Q2 2026 revenue of $8.07 million, up 50.9% sequentially, with gross profit increasing 161.2% YoY. The company invested heavily in R&D, especially in 5G and MMIC technologies, and strengthened its balance sheet with a successful Series A rights offering. It c…
Elutia Inc. announced securing up to $26 million in funding to support the FDA clearance and full commercial launch of its antibiotic-eluting biomatrix product, NXT-41x, without issuing new equity. The company reported Q2 2026 financials showing a net loss of $7.6 million but progresses on regulatory and manufacturing milestones with strong surgeon…
Xos, Inc. reported significant improvements in its first-half 2026 financials, expanding GAAP gross margin from 11.8% to 31.0% and non-GAAP gross margin from 4.9% to 29.0% year-over-year. The company reduced operating expenses by 8.6%, narrowed operating losses substantially, and improved EBITDA metrics while launching the new Power Hub energy stor…
Celcuity Inc. reported second quarter 2026 financial results and corporate updates highlighting the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer, with commercial launch expected in Q3 2026. The company also announced positive Phase 3 VIKTORIA-1 trial results in the PIK3CA mutant cohort, supporting a …
Midera Food Processing, newly independent from The Middleby Corporation as of July 2026, reported a 13.2% increase in net sales to $245 million in Q2 2026 alongside a 16% increase in orders and a record backlog of $446 million. Despite a decline in net earnings compared to the prior year, the company posted a 10.6% increase in estimated standalone …
Glass House Brands Inc. reported its second quarter 2026 financial results featuring record cannabis biomass production of 246,000 pounds at a cost of $122 per pound, improved from the prior quarter. The company completed the deconsolidation of its dual-use retail business, focusing on a medically licensed, Schedule III compliant model. Revenue was…
Eledon Pharmaceuticals reported its Q2 2026 financial results highlighting successful regulatory interactions and strong clinical data for tegoprubart in kidney and islet cell transplantation. The company is on track to start a global Phase 3 kidney transplant trial in late 2026 with promising long-term Phase 2 results showing improved kidney funct…
nCino, Inc., a US-based platform specializing in agentic AI banking for financial institutions, announced it will release its second quarter fiscal year 2027 financial results on August 25, 2026, after market close, followed by a conference call to discuss the results.
MDB Capital Holdings announced its Q2 2026 operational and financial update, showcasing successful underwriting of IPOs including Buda Juice, Ticketplus, and eXoZymes. The company expanded its pipeline of disruptive technology ventures, progressed strategic partnerships to enhance distribution, and initiated the spin-out of its AI-driven PatentVest…
MacroGenics announced solid second quarter 2026 financial results highlighted by $32.8 million in revenue driven by milestone payments, net income of $19.5 million including discontinued operations, and a strengthened cash position of $327 million after the sale of its manufacturing operations. The company is transitioning to an outsourced manufact…
CapsoVision, a medical technology company specializing in AI-enabled capsule endoscopy, reported Q2 2026 revenue of $3.6 million, up 10% year-over-year. The company launched its AI Highlights™ product in the EU and expects FDA clearance and U.S. launch by Q3 end. Product adoption across hospitals and GI networks is expanding, and the CapsoCam Colon…
Quantum-Si Incorporated announced its Q2 2026 financial results, highlighting a delay in the commercial launch of its Proteus protein sequencing platform to Q2 2027 for additional development and manufacturing readiness. The company recorded $344 thousand in revenue during the Proteus transition period, implemented a 20% workforce reduction to alig…
Roadzen Inc. announced its best quarter ever with Q1 FY2027 revenue of $16.2 million, up 49% year-over-year, driven by strong adoption of its AI platform in insurance and mobility sectors. The company improved adjusted EBITDA loss by 73% and signed a definitive agreement to acquire a European MGA specializing in short-term car rental insurance, exp…
4D Molecular Therapeutics reported strong second quarter 2026 results including completion of enrollment for its 4FRONT-2 Phase 3 trial for wet AMD, and expects topline data from both 4FRONT-1 and 4FRONT-2 trials in 2027. The company also presented positive 2-year Phase 2b data for 4D-150 and plans to initiate a Phase 3 trial for diabetic macular e…
Equillium, Inc. reported second quarter 2026 financial results highlighting progress toward clinical development of EQ504, a selective AhR modulator for autoimmune and inflammatory disorders. The company expects to initiate a Phase 1 proof-of-mechanism study in Q4 2026, with topline data anticipated about six months later. Equillium maintains a str…
PEDEVCO Corp. reported a substantial increase in revenue and net income for Q2 2026, driven by a 348% increase in production and higher oil prices following the October 2025 merger that expanded its asset base. Adjusted EBITDA rose 516% to $18.7 million, reflecting improved operational scale and financial performance. The company initiated an enhan…
Eton Pharmaceuticals reported strong Q2 2026 results with record product sales of $37.6 million, reflecting 99% growth year-over-year. The company achieved positive GAAP and non-GAAP earnings per share, expanded its rare disease portfolio with the licensing of the late-stage product ASN-001, and raised full-year revenue guidance to exceed $145 mill…
Dynagas LNG Partners LP announced a quarterly cash distribution of $0.050 per common unit for the quarter ended June 30, 2026, payable on August 28, 2026. The Partnership owns six LNG carriers operating on multi-year charters with a combined carrying capacity of approximately 914,000 cubic meters.
Jefferson Capital, Inc., a purchaser and manager of consumer receivables, announced its second quarter 2026 results highlighting an 18% increase in collections to $300.9 million and a 21% rise in deployments to $152.2 million. Estimated Remaining Collections grew 18% to $3.4 billion. The company reported pre-tax income of $53.3 million and net inco…
Capricor Therapeutics reported Q2 2026 financial results along with updates on the regulatory review of Deramiocel, their lead cell therapy for Duchenne muscular dystrophy (DMD). The FDA advisory committee voted 9-3 against substantial evidence of effectiveness of Deramiocel for treating cardiomyopathy in DMD, impacting approval prospects. However,…
Xcel Brands, Inc. reported its Q2 2026 financial results featuring a net loss of $2.5 million on a GAAP basis, an improvement compared to $4.0 million loss in the prior year quarter. Adjusted EBITDA showed a 40% improvement when excluding non-recurring expenses, driven by new influencer-led product launches and reduced operating expenses. Revenue d…
AVAX One Technology Ltd. (NASDAQ: AVX) announced its Q2 2026 financial results showing a substantial increase in total revenue to $2.8 million from $0.5 million a year earlier, primarily driven by $2.1 million in staking rewards from its Avalanche digital asset treasury and $0.7 million from bitcoin mining. Despite revenue growth, the company repor…
